Endpoint-only views lack the cross-domain context and timeliness needed for prevention. Using multiple point solutions for different aspects of security only increases dashboard fatigue, making it ...

Endpoint management has become more challenging for IT teams as organisations adopt remote work, cloud services, and a wider ...

Investing.com -- AstraZeneca PLC (ST:AZN) announced Monday that its LATIFY Phase III trial of ceralasertib in combination ...

Compare leading authentication platforms like Okta, Auth0, and open-source tools. Find the best authentication system for your business needs, balancing security, cost, and scalability.

Ipsen’s phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva fails to meet primary endpoint: Paris, France Monday, December 22, ...

The tech firm reveals a focus on AI agents, Copilot expansion, Microsoft 365 updates, and global infrastructure investment.

Investing.com -- AstraZeneca PLC (NASDAQ:AZN) announced Monday that its LATIFY Phase III trial of ceralasertib failed to meet its primary endpoint in non-small cell lung cancer (NSCLC).

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid ...

Although there are several effective anti-osteoporosis drugs on the market today, new therapies with improved safety profiles and efficacy are still needed. The FDA called osteoporosis-related ...

At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen ...

Discover why CrowdStrike Holdings, Inc. is the top cybersecurity stock for 2026, showing rapid growth and big upside. Click for this CRWD stock update.

Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest ...